PMID- 29972992
OWN - NLM
STAT- MEDLINE
DCOM- 20180711
LR  - 20181202
IS  - 1002-0098 (Print)
IS  - 1002-0098 (Linking)
VI  - 53
IP  - 5
DP  - 2018 May 9
TI  - [Semaphorin 3A-stimulated bone marrow mesenchymal stem cells sheets promotes 
      osteogenesis of type 2 diabetic rat].
PG  - 333-338
LID - 10.3760/cma.j.issn.1002-0098.2018.05.009 [doi]
AB  - Objective: To evaluate the effect of semaphorin 3A (Sema3A) pre-treated bone 
      marrow mesenchymal stem cells (BMSC) sheets on new bone formation in type 2 
      diabetes mellitus rats. Methods: Type 2 diabetes mellitus (T2DM) were induced by 
      injection of streptozotocin, and the BMSC were isolated, controlled, identified 
      and induced into cell sheets. Fifteen T2DM rats were randomly divided into 
      control, sheets and Sema3A-sheets group and the calvarial critical size defect 
      (CSD) model of rats were established. The defect zone of rats from control group 
      were implanted with bone powder. The defect zone of rats from sheets group were 
      implanted with bone powder and BMSC sheets. The defect zone of rats from 
      Sema3A-sheets group were implanted with bone powder and BMSC sheets pretreated 
      with 1.0 mg/L Sema3A. After 8 weeks, the bone samples were harvested and analyzed 
      by micro-CT scanning, HE staining for the evaluation of new bone formation, and 
      the immunohistochemical analysis for the expression of osteogenesis-related 
      proteins including type Ⅰ collagen (COL- Ⅰ ), bone morphogenetic protein-2 
      (BMP-2), and osteocalcin (OCN). Results: The BMSC were isolated and cultured, and 
      oil red O and Alizarin red S staining proved the multi-potential differentiation. 
      Eight weeks after the establishment of calvarial CSD model, Sema3A-sheet group 
      showed the most abundant new bone formation (0.516+/-0.070), with increased bone 
      volume fraction, namely bone volume/tissue volume (BV/TV) compared with sheets 
      group (0.319+/-0.050) and control group (0.224+/-0.037) (P<0.05), and the sheets 
      group showed increased BV/TV compared with control group (P<0.05). While 
      trabecular thickness (Tb.Th) control group showed no difference in three groups 
      (P>0.05). HE staining also confirmed that Sema3A-sheets group showed the most new 
      bone formation. Sheet group (0.174+/-0.051) compared showed difference with control 
      group (0.099+/-0.033) (P< 0.05), and Sema3A-sheet group (0.421+/-0.069) showed 
      increased bone formation compared with sheet group and control group (P<0.05). 
      Immunohistochemistry showed that BMSC sheet increased the expression of 
      osteogenesis-related proteins including COL-Ⅰ, BMP-2 and OCN, while Sema3A 
      pretreatment showed more obvious increase of the expression of COL-Ⅰ and OCN. 
      Conclusions: The combined implantation of bone powder and Sema3A stimulated BMSC 
      sheets significantly increased bone regeneration in vivo. Therefore, Sema3A 
      pre-treated BMSC sheets transplantation provides a new strategy for restoring 
      bone defect in T2DM.
FAU - Qiao, Q
AU  - Qiao Q
AD  - Department of Stomatology, Shanxi Medical University, Taiyuan 030012, China.
FAU - Song, Y L
AU  - Song YL
AD  - Department of Implantation, School of Stomatology, The Fourth Military Medical 
      University & State Key Laboratory of Military Stomatology & National Clinical 
      Research Center for Oral Diseases & Shaanxi Engineering Research Center for 
      Dental Materials and Advanced Manufacture, Xi'an 710032, China.
FAU - Li, F L
AU  - Li FL
AD  - Department of Prosthodontics, People's Hospital Affiliated to Shanxi Medical 
      University, Taiyuan 030012, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Kou Qiang Yi Xue Za Zhi
JT  - Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese 
      journal of stomatology
JID - 8711066
RN  - 0 (Bmp2 protein, rat)
RN  - 0 (Bone Morphogenetic Protein 2)
RN  - 0 (Bone Morphogenetic Proteins)
RN  - 0 (Collagen Type I)
RN  - 0 (Semaphorin-3A)
RN  - 104982-03-8 (Osteocalcin)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells
MH  - Bone Morphogenetic Protein 2/metabolism
MH  - Bone Morphogenetic Proteins
MH  - *Bone Transplantation/methods
MH  - Bone and Bones
MH  - Cell Differentiation
MH  - Collagen Type I/metabolism
MH  - Diabetes Mellitus, Type 2/chemically induced/*physiopathology
MH  - Mesenchymal Stem Cells/*drug effects/physiology
MH  - Osteocalcin/metabolism
MH  - Osteogenesis/*drug effects/physiology
MH  - Random Allocation
MH  - Rats
MH  - Semaphorin-3A/*pharmacology
MH  - X-Ray Microtomography
OTO - NOTNLM
OT  - Bone regeneration
OT  - Diabetes mellitus, type 2
OT  - Mesenchymal stem cells
OT  - Semaphorin-3A
EDAT- 2018/07/06 06:00
MHDA- 2018/07/12 06:00
CRDT- 2018/07/06 06:00
PHST- 2018/07/06 06:00 [entrez]
PHST- 2018/07/06 06:00 [pubmed]
PHST- 2018/07/12 06:00 [medline]
AID - 10.3760/cma.j.issn.1002-0098.2018.05.009 [doi]
PST - ppublish
SO  - Zhonghua Kou Qiang Yi Xue Za Zhi. 2018 May 9;53(5):333-338. doi: 
      10.3760/cma.j.issn.1002-0098.2018.05.009.